Frost & Sullivan Lauds Veran Medical for its IG4 Plug-n-Play Navigation System

March 2, 2009

MOUNTAIN VIEW, Calif., March 2 /PRNewswire/ — Based on its recent
analysis of image guided therapy markets, Frost & Sullivan presents Veran
Medical Technologies, Inc. with the 2009 North American Frost & Sullivan Award
for Technology Innovation of the Year in recognition of its pioneering
development of a novel image guided medical therapy delivery system, known as
the IG4, which enables accurate and efficient targeting of very small lesions
in the lungs. The technology is unique, as it is based on a 4-D registration
principle. Unlike traditional navigation technologies, by encouraging the
movement of fiducials, the IG4 technology helps solve the problem of
maintaining accurate localization for moving organs.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Current lung cancer detection protocols require patients with small
lesions to come back repeatedly for computed tomography (CT) scans to monitor
their growth. Multiple scans translate to increased costs and increased
radiation exposure. In addition, physicians do not possess the means to
integrate multiple modality information such as PET-CT, MR-CT, or contrasted
enhanced images for real-time navigation in the CT suite.

“In this context, image guided technologies are proving their usefulness
especially in fields such as neurosurgery and functional endoscopic surgery,”
says Frost & Sullivan Industry Analyst Pramodh Ishwarakrishnan. “With its 4D
registration features, Veran Medical’s IG4 system represents a complete
solution for the early diagnosis of lung cancer.”

The time-saving IG4 Plug-n-Play Delivery System uses real-time
electromagnetic localization to track organ motion and deliver diagnostic
biopsy needles and therapy devices. The advantage of the IG4 is that it
requires no user interaction to complete registration. The system incorporates
advanced auto-segmentation and proprietary design for patient tracking, which
serves to eliminate the possibility of user error being introduced into the
system through the process of manually selecting registration fiducials both
in the image and on the patient.

In fact, Veran Medical has a wide array of tracking devices from universal
adapters that can be applied to any vendor’s biopsy and ablation needles to
its own proprietary tip-tracked biopsy needles that have localization sensors
integrated at the tip of the device. Tip-tracked needles help enable very fine
gauge needles to be accurately navigated.

Further, the IG4 enables physicians to navigate needles without the added
radiation exposure that physicians and hospital staff are subjected to by
using CT Fluoro. Another major benefit is that it is not limited to navigating
in a single plane or on lower quality images that CT Fluoro requires. The IG4
allows a physician to select any approach to target the lesion with its global
positioning system-like accuracy for high-quality images.

What differentiates Veran’s 4-D registration principle from those of its
competitors is that it includes an automatic 3-D spatial registration between
the electromagnetic field generator and the real-time CT scans of the patient
anatomy, and a temporal registration capable of determining when the patient
is at the same point in the respiratory cycle as when the CT scan was
acquired. While competing technologies implement traditional rigid 3-D
registration algorithms, they fail to take into account the inaccuracies
caused by patient motion.

“With its multitude of benefits, Veran’s technology has the potential to
become the standard of care for soft tissue applications,” notes
Ishwarakrishnan. “Its ability to track the patient’s real-time respiratory
motion and navigate the tip of needles to very small lesions while reducing
time of the procedure represents an optimal solution. Moreover, the system is
capable of integrating multimodality image information and real-time
navigation, which in turn increases the strength of individual imaging
modalities. Also, IG4′s single shot delivery of contrast agents and subsequent
navigation to it is another valuable capability.”

The Veran IG4 Navigation System has been granted 510 K clearances and the
company is expecting to begin commercialization in international markets. It
closed its first round of $4.75 million in venture capital and private
financing in April 2008 and secured its first U.S. Patent 7,398,116 in July

Clearly on a path to positive growth, Veran Medical’s technology could
help reduce procedure times and increase accuracy by tracking lung cancer
patient’s real-time respiratory motion, thus enabling physicians to treat them
more effectively. In recognition, Frost & Sullivan is proud to present Veran
Medical with the 2009 Award for Technology Innovation of the Year Award in the
image guided therapy markets.

Each year, Frost & Sullivan presents this award to the company that has
carried out new research, which has resulted in innovations that have or are
expected to bring significant contributions to the industry in terms of
adoption, change, and competitive posture. This award recognizes the quality
and depth of a company’s research and development program as well as the
vision and risk-taking that enabled it to undertake such an endeavor.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts compare
market participants and measure performance through in-depth interviews,
analysis, and extensive secondary research in order to identify best practices
in the industry.

About Veran Medical Technologies, Inc.

Veran Medical Technologies is a privately held image guided medical device
company focused on developing the next standard of care for minimally invasive
delivery of interventional oncology therapies. Veran provides proprietary 4D
registration capability for precise targeting of lesions via its FDA cleared
platform. The Veran platform aims to reduce procedure times, reduce radiation
exposure for the clinical staff, and increase targeting accuracy enabling
physicians to cost effectively treat patients with reduced co-morbidity risk.
Veran Medical Technologies is headquartered in St. Louis, MO. To learn more
about Veran Medical Technologies, please visit our website at

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best in class positions in growth, innovation
and leadership. The company’s Growth Partnership Service provides the CEO and
the CEO’s Growth Team with disciplined research and best practice models to
drive the generation, evaluation and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 31 offices on six continents. To join our Growth Partnership,
please visit http://www.frost.com.

     Jake Wengroff

SOURCE Frost & Sullivan

Source: newswire

comments powered by Disqus